Hao Ran

680 total citations
45 papers, 494 citations indexed

About

Hao Ran is a scholar working on Neurology, Immunology and Molecular Biology. According to data from OpenAlex, Hao Ran has authored 45 papers receiving a total of 494 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Neurology, 11 papers in Immunology and 7 papers in Molecular Biology. Recurrent topics in Hao Ran's work include Myasthenia Gravis and Thymoma (12 papers), Parkinson's Disease and Spinal Disorders (5 papers) and Peripheral Neuropathies and Disorders (4 papers). Hao Ran is often cited by papers focused on Myasthenia Gravis and Thymoma (12 papers), Parkinson's Disease and Spinal Disorders (5 papers) and Peripheral Neuropathies and Disorders (4 papers). Hao Ran collaborates with scholars based in China, United States and United Kingdom. Hao Ran's co-authors include Xue‐Qiang Zha, Jian‐Ping Luo, Jian Liu, Xin Pan, Chuanbin Wu, Li‐Hua Pan, Song-Zi Xie, Guilan Quan, Tingting Peng and Weibin Liu and has published in prestigious journals such as Food Chemistry, Biochemical and Biophysical Research Communications and Carbohydrate Polymers.

In The Last Decade

Hao Ran

40 papers receiving 493 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hao Ran China 11 122 104 89 68 67 45 494
Eman Sheta Egypt 13 51 0.4× 167 1.6× 26 0.3× 21 0.3× 33 0.5× 58 467
Alessandra Marini Germany 17 40 0.3× 148 1.4× 16 0.2× 13 0.2× 51 0.8× 37 899
Ana Flávia Marçal Pessoa Brazil 12 28 0.2× 158 1.5× 24 0.3× 7 0.1× 46 0.7× 28 632
Jamin A. Willoughby Poland 14 18 0.1× 137 1.3× 42 0.5× 6 0.1× 57 0.9× 25 603
Sushma Verma India 12 235 1.9× 183 1.8× 32 0.4× 28 0.4× 40 0.6× 35 569
Zeyu Liu China 12 98 0.8× 269 2.6× 19 0.2× 28 0.4× 115 1.7× 27 583
Alain Coquette Belgium 10 92 0.8× 106 1.0× 16 0.2× 6 0.1× 93 1.4× 14 672
Diane Berson United States 20 109 0.9× 80 0.8× 21 0.2× 8 0.1× 68 1.0× 37 1.4k
Fengyuan Chen China 12 25 0.2× 227 2.2× 32 0.4× 8 0.1× 69 1.0× 16 520
Mitchell Wortzman United States 16 32 0.3× 62 0.6× 33 0.4× 80 1.2× 79 1.2× 36 636

Countries citing papers authored by Hao Ran

Since Specialization
Citations

This map shows the geographic impact of Hao Ran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hao Ran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hao Ran more than expected).

Fields of papers citing papers by Hao Ran

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hao Ran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hao Ran. The network helps show where Hao Ran may publish in the future.

Co-authorship network of co-authors of Hao Ran

This figure shows the co-authorship network connecting the top 25 collaborators of Hao Ran. A scholar is included among the top collaborators of Hao Ran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hao Ran. Hao Ran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Huanhuan, Yuxin Chen, Fuping Zhang, et al.. (2025). rTMS ameliorates CUMS-induced anxiety-depression-like behaviour and cognitive dysfunction in rats by modulating the COX-2/PGE2 signalling pathway. Journal of Psychiatric Research. 186. 116–128. 3 indexed citations
2.
Ran, Hao, Jianmin Huang, Xintong Zhang, et al.. (2025). P0848 Engineering and Development of a Novel Bispecific Antibody Targeting both TL1A and α4β7 for the Treatment of IBD. Journal of Crohn s and Colitis. 19(Supplement_1). i1618–i1618. 1 indexed citations
3.
4.
Wu, Jingyu, Yi Ou, Min Yao, et al.. (2025). The immunostimulatory activity of Epimedium flavonoids involves toll-like receptor 7/8. Frontiers in Pharmacology. 16. 1514284–1514284. 1 indexed citations
5.
Huang, Jianyong, Hao Ran, Xintong Zhang, et al.. (2025). P1114 Engineering and Development of a Novel Bispecific Antibody Targeting IL-23 and TL1A. Journal of Crohn s and Colitis. 19(Supplement_1). i2046–i2046. 2 indexed citations
6.
7.
Lin, Jianzhe, et al.. (2025). Deciphering the gastrointestinal fate of four heat-treated legume proteins: Focus on digestive characteristics and peptide profiles. International Journal of Biological Macromolecules. 319(Pt 2). 145522–145522.
8.
Ran, Hao, Yingyong Hou, Di Wang, et al.. (2025). Comparison of the efficacy of high-definition transcranial direct current stimulation and transcranial magnetic stimulation in the treatment of depression. Journal of Neurorestoratology. 13(3). 100190–100190.
9.
Ran, Hao, Tong Zhao, Xinxin Lu, et al.. (2024). CUMS induces depressive-like behaviors and cognition impairment by activating the ERS-NLRP3 signaling pathway in mice. Journal of Affective Disorders. 369. 547–558. 4 indexed citations
10.
Lu, Yaru, Qian Ma, Huan Huang, et al.. (2023). JAK2 inhibitor ameliorates the progression of experimental autoimmune myasthenia gravis and balances Th17/Treg cells via regulating the JAK2/STAT3-AKT/mTOR signaling pathway. International Immunopharmacology. 115. 109693–109693. 19 indexed citations
11.
12.
Ma, Qian, Hao Ran, Xiaoxi Liu, et al.. (2021). Is myasthenia gravis a contraindication for botulinum toxin?. Journal of Clinical Neuroscience. 95. 44–47. 3 indexed citations
13.
Huang, Xin, Qiu Li, Yaru Lu, et al.. (2021). Clinical evaluation of efficacy of leflunomide combined with low-dose prednisone for treatment of myasthenia gravis. Acta Neurologica Belgica. 123(1). 153–160. 4 indexed citations
14.
Lu, Yaru, Hao Ran, Wenhao Yang, et al.. (2020). AChR myasthenia gravis switching to MuSK or double antibody positive myasthenia gravis in two children and literature review. Neuromuscular Disorders. 30(7). 534–538. 6 indexed citations
15.
Fang, Wei, Yan Li, Jianjian Wang, et al.. (2020). Hospital and healthcare insurance system record–based epidemiological study of myasthenia gravis in southern and northern China. Neurological Sciences. 41(5). 1211–1223. 17 indexed citations
16.
Ma, Qian, Hao Ran, Yingkai Li, et al.. (2020). Circulating Th1/17 cells serve as a biomarker of disease severity and a target for early intervention in AChR-MG patients. Clinical Immunology. 218. 108492–108492. 15 indexed citations
17.
Ran, Hao, Guilan Quan, Ying Huang, et al.. (2018). The practical self-targeted oncolytic adenoviral nanosphere based on immuno-obstruction method via polyprotein surface precipitation technique enhances transfection efficiency for virotherapy. Biochemical and Biophysical Research Communications. 508(3). 791–796. 5 indexed citations
18.
Quan, Guilan, Tingting Peng, Chune Zhu, et al.. (2017). Novel strategy for immunomodulation: Dissolving microneedle array encapsulating thymopentin fabricated by modified two-step molding technology. European Journal of Pharmaceutics and Biopharmaceutics. 122. 104–112. 31 indexed citations
19.
Quan, Guilan, Tingting Peng, Qingqing Wang, et al.. (2017). Novel dissolving microneedles for enhanced transdermal delivery of levonorgestrel: In vitro and in vivo characterization. International Journal of Pharmaceutics. 534(1-2). 378–386. 85 indexed citations
20.
Xie, Song-Zi, Hao Ran, Xue‐Qiang Zha, et al.. (2016). Polysaccharide of Dendrobium huoshanense activates macrophages via toll-like receptor 4-mediated signaling pathways. Carbohydrate Polymers. 146. 292–300. 103 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eman Sheta Breakdown of academic impact, for papers by Alessandra Marini Breakdown of academic impact, for papers by Ana Flávia Marçal Pessoa Breakdown of academic impact, for papers by Jamin A. Willoughby Breakdown of academic impact, for papers by Sushma Verma Breakdown of academic impact, for papers by Zeyu Liu Breakdown of academic impact, for papers by Alain Coquette Breakdown of academic impact, for papers by Diane Berson Breakdown of academic impact, for papers by Fengyuan Chen Breakdown of academic impact, for papers by Mitchell Wortzman
Rankless by CCL
2026